<SEC-DOCUMENT>0001437749-25-037025.txt : 20251205
<SEC-HEADER>0001437749-25-037025.hdr.sgml : 20251205
<ACCEPTANCE-DATETIME>20251205160542
ACCESSION NUMBER:		0001437749-25-037025
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20251201
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251205
DATE AS OF CHANGE:		20251205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		251552977

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crvo20251205_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:crvo="http://www.crvo.com/20251201"><head>
	<title>crvo20251205_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 12/5/2025 6:08:13 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20258K" name="dei:AmendmentFlag" id="ixv-335">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20258K" name="dei:EntityCentralIndexKey" id="ixv-336">0001053691</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="crvo-20251201.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20258K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-12-01</xbrli:startDate>
<xbrli:endDate>2025-12-01</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20258K" name="dei:DocumentType" id="ixv-346">8-K</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-347">December 1, 2025</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityRegistrantName" id="ixv-348">CervoMed Inc.</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-349">Delaware</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: top; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityFileNumber" id="ixv-350">001-37942</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityTaxIdentificationNumber" id="ixv-351">30-0645032</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(State or other jurisdiction</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>of incorporation)</b></div>
			</td>
			<td style="vertical-align: top; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Commission</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>File Number)</b></div>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identification No.)</b></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine1" id="ixv-352">20 Park Plaza</ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine2" id="ixv-353">Suite 424</ix:nonNumeric></b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressCityOrTown" id="ixv-354">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-355">Massachusetts</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressPostalZipCode" id="ixv-356">02116</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Address of principal executive offices)</b></div>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Zip Code)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d20258K" name="dei:CityAreaCode" id="ixv-357">617</ix:nonNumeric>) <ix:nonNumeric contextRef="d20258K" name="dei:LocalPhoneNumber" id="ixv-358">744-4400</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-359">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-360">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-361">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-362">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Trading</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Name of each exchange</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>on which registered</b></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:Security12bTitle" id="ixv-363">Common Stock</ix:nonNumeric>, $0.001 par value</div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:TradingSymbol" id="ixv-364">CRVO</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-365">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-366">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 7.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Regulation FD Disclosure</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Press Releases</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On December 2, 2025, CervoMed Inc. (the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) issued a press release (the &#8220;December 2 Press Release&#8221;) announcing new plasma biomarker data from our Phase 2b RewinD-LB trial (the &#8220;RewinD-LB Trial&#8221;) demonstrating neflamapimod treatment led to improvements in neuroinflammation and neurodegeneration in patients with dementia with Lewy bodies (&#8220;DLB&#8221;) presented at the 18<sup style="vertical-align:top;line-height:120%;">th</sup> Clinical Trials on Alzheimer's Disease (&#8220;CTAD&#8221;) Conference in San Diego, California on December 1, 2025. A copy of the December 2 Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On December 4, 2025, we issued a press release (the &#8220;December 4 Press Release&#8221;) announcing that clinical investigators shared the full results of the RewinD-LB Trial in a late-breaking oral session at the CTAD Conference on December 4, 2025. A copy of the December 4 Press Release is attached hereto as Exhibit 99.2 and incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Presentations</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company, including the data and other information from the RewinD-LB Trial presented at the CTAD Conference, has been made available on our website, www.cervomed.com, under the heading, &#8220;Investors &#8211; Events and Presentations.&#8221; Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the presentation is summary information that is intended to be considered in the context of the Company&#8217;s filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">--</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information in this Item 7.01 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 8.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Other Events </b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information set forth, (i) with respect to the December 2 Press Release, in the first two paragraphs and under the heading, &#8220;Treatment Benefit Associated with Biomarker Measurements,&#8221; and (ii) with respect to the December 4 Press Release, in the first paragraph and under the heading, &#8220;Results from the Phase 2b RewinD-LB Trial,&#8221; is incorporated by reference into this Item 8.01 of this Current&#160;Report&#160;on&#160;Form&#160;8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 9.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>(d)</i></b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Exhibits</i></b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following exhibit relating to Item 7.01 is furnished and not filed:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="width: auto; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&#160;</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">99.1</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><a href="ex_896196.htm" style="-sec-extract:exhibit;">Press Release, issued December 2, 2025</a></div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">99.2</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><a href="ex_896197.htm" style="-sec-extract:exhibit;">Press Release, issued December 4, 2025</a></div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: December 5, 2025</div>
			</td>
			<td colspan="2" style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>CervoMed Inc.</b></div>
			</td>
			<td style="vertical-align: middle; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ William Elder</div>
			</td>
			<td style="vertical-align: middle; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name:</div>
			</td>
			<td style="vertical-align: middle; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">William Elder</div>
			</td>
			<td style="vertical-align: middle; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Title:</div>
			</td>
			<td style="vertical-align: middle; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer &amp; General Counsel</div>
			</td>
			<td style="vertical-align: middle; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_896196.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_896196.htm</title>

	<!-- Generated by ThunderDome Portal - 12/5/2025 6:31:19 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<div><img alt="logosmlr.jpg" src="logosmlr.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly&nbsp;Improves Neuroinflammation and Neurodegeneration in </b><br>
<b>Dementia with Lewy Bodies (DLB)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>1st of two presentations with results from Phase 2b study of neflamapimod at the 18</i><i><sup style="vertical-align:top;line-height:120%;">th</sup></i><i> Clinical Trials on Alzheimer's Disease (CTAD) Conference</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein</i> (<i>GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A</i>b<i>) 42/40 ratio in DLB</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Correlation of the effects of neflamapimod on plasma GFAP with positive treatment response, as assessed by CDR-SB, support neflamapimod mechanism of action and suggest it may act on underlying disease </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BOSTON, December 2, 2025</b> &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, has shared new data from the Phase 2b RewinD-LB trial demonstrating neflamapimod treatment led to a significant reduction in the widely used neurodegeneration biomarker plasma GFAP and an increase in Ab42/40 ratio, an inverse marker of neuroinflammation and amyloidogenesis. In addition, neflamapimod treatment showed a trend towards reducing plasma neurofilament light (NfL) chains levels.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These data were presented on December 1, 2025, at the 18<sup style="vertical-align:top;line-height:120%;">th</sup> Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California. A second presentation will take place in an oral late-breaking session at the conference on December 4th, 2025, in which Dr. John-Paul Taylor, MBBS, MRCPsych, PhD, Professor of Translational Dementia Research at Newcastle University, will provide the clinical outcome results from RewinD-LB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;The reduction in plasma GFAP levels and the increase in the Ab42/40 ratio, as well as the signal of activity on NfL chain levels indicates to me that neflamapimod broadly improves the neuroinflammatory and neurodegenerative profile in the brain of DLB patients,&#8221; said Charlotte Teunissen, PhD, Professor of Neurochemistry at Amsterdam University Medical Center and global leader in the development and validation of fluid biomarkers for neurodegenerative diseases. understanding and treating. &#8220;The correlation between the clinical benefit of neflamapimod treatment and plasma GFAP both validates plasma GFAP as a biomarker of neurodegenerative disease activity in DLB and strengthens the conclusions of neflamapimod&#8217;s clinical effects. It is encouraging to see that we are making progress in understanding and treating this devastating disease.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink"><img alt="logosmlr.jpg" src="logosmlr.jpg"></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;The biomarker data presented at CTAD reinforces the results of our previous Phase 2a study and demonstrates a significant correlation between the reduction of plasma GFAP and the slowing of clinical progression in people with DLB,&#8221; said Dr. John Alam, Chief Executive Officer of CervoMed. &#8220;These results highlight the utility of biomarkers such as plasma GFAP and the A&#946;42/40 ratio in DLB and suggest that neflamapimod may be acting on the underlying disease process. Together, these findings further strengthen our confidence as we move toward our upcoming Phase 3 trial.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DLB is the second most common progressive dementia after Alzheimer&#8217;s disease (AD), affecting millions worldwide, and has no approved treatments in the United States or European Union. DLB progresses more rapidly than AD, with average time from diagnosis to requiring nursing home care being two years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Treatment Benefit Associated with Biomarker Measurements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In DLB, there are multiple biomarkers that have been shown to be closely associated with the underlying disease process and progression of neuronal dysfunction and loss. GFAP is widely recognized as an indicator of astrocyte degeneration and reactivity, and GFAP levels become elevated as patients with DLB progress. Lower A&#946;42/40 ratios have been demonstrated to be associated with increased amyloid plaque burden.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The RewinD-LB Phase 2b study was comprised of an initial, randomized phase comparing neflamapimod to placebo, followed by an open-label, neflamapimod-only extension phase, or the Extension. Based on the results of the Phase 2a study and extensive published literature documenting GFAP as a key biomarker of neurodegeneration, change in plasma GFAP was prospectively defined as the biomarker endpoint. In the randomized phase of the Phase 2b, patients did not achieve expected plasma drug concentration levels with the neflamapimod capsules used (DP Batch A), and neflamapimod did not demonstrate a statistically significant improvement on the study&#8217;s primary clinical endpoint, nor on plasma GFAP levels. The lower&#8211;than-expected bioavailability was subsequently determined to be related to the age of the capsules used during this phase of the study.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink"><img alt="logosmlr.jpg" src="logosmlr.jpg"></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the extension phase, a group of participants received a new batch of capsules that enabled them to achieve target plasma concentration levels (DP Batch B). Outcomes in participants receiving DP Batch B during the extension phase were compared with participants who received DP Batch A during the extension phase, which served as a control arm, as well to outcomes in the same participants during the randomized phase in those who received placebo initially.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">During the 32 weeks of the Extension there was a significant reduction in plasma GFAP levels in participants who received DP Batch B (median -16.0, IQR: -35, +6.7; p&lt;0.0001 for change from start to Week 32 of the Extension).</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Change in plasma GFAP over 32 weeks was significantly lower during treatment with DP Batch B (mean -16.7 pg/mL) compared to change in the same participants during placebo administration (mean +5.8 pg/mL) over 16 weeks (median difference = -23.5 pg/mL, p=0.016, Wilcoxon rank sum test). This analysis was restricted to the patients (N=48) who received placebo during the randomized period and then received DP Batch B during the Extension,</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The reduction in plasma GFAP associated with neflamapimod treatment was positively correlated to change in CDR-SB over the 32 weeks of the extension phase (r=.35, p=0.036).</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">32 weeks of treatment during the extension with neflamapimod also significantly increased Ab42/40 ratio (p&lt;0.001 compared to start of extension) and showed a trend towards reducing NfL levels. In line with the recent published literature regarding NfL levels in patients with DLB, and in contrast to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), NfL levels were only minimally elevated in the RewinD-LB at study entry, which provided insufficient signal to definitively demonstrate treatment effects on NfL in this context.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Trial in Dementia with Lewy Bodies</b><br>
The initial phase of RewinD-LB was a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in 159 participants with DLB, followed by a 32-week neflamapimod-only treatment extension phase. Patients with AD co-pathology, as assessed by plasma ptau181 levels, were excluded from the trial. The primary endpoint in the trial is change in the CDR-SB, and secondary endpoints include the ADCS-CGIC, the Timed Up and Go test, and a cognitive test battery. The RewinD-LB trial was funded primarily by a&nbsp;$21.3 million&nbsp;grant from the&nbsp;National Institutes&nbsp;of Health&#8217;s&nbsp;National Institute on Aging, disbursed over the course of the trial as costs were incurred. The trial included 43 sites across in&nbsp;the United States, the&nbsp;United Kingdom, and&nbsp;the Netherlands.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink"><img alt="logosmlr.jpg" src="logosmlr.jpg"></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Dementia with Lewy Bodies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DLB is the second most common progressive dementia after AD, affecting millions worldwide. Patients may experience a combination of decline in cognitive function, cognitive fluctuations, visual hallucinations, and sleep disorders, as well as motor symptoms similar to Parkinson&#8217;s disease. There are no approved treatments for DLB in the United States or European Union, and the current standard-of-care therapies only temporarily relieve symptoms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral, small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed&#8217;s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Neflamapimod</b><br>
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood&#8211;brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and frontotemporal dementia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In non-clinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week open-label extension, further supported neflamapimod&#8217;s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing a positive effect on a key blood biomarker of neurodegeneration during the extension phase. Across both studies, the greatest benefits were observed in patients with &#8220;pure&#8221; DLB, those without AD co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink"><img alt="logosmlr.jpg" src="logosmlr.jpg"></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic effects and the meaningfulness of any correlation between any biomarker and clinical effects; the anticipated timing and achievement of clinical and development milestones, including the Company&#8217;s announcement of additional data or any meeting or correspondence between the Company and the FDA or other regulatory bodies; any other expected or implied benefits or results, including that any clinical results observed with respect to neflamapimod in the RewinD-LB trial will be replicated in later trials, including the Company&#8217;s planned&nbsp;Phase 3&nbsp;clinical trial evaluating the efficacy and safety of neflamapimod in patients with DLB; the timing of the initiation of and the design and endpoints of, any potential future trials, including the Company&#8217;s planned&nbsp;Phase 3&nbsp;clinical trial evaluating the efficacy and safety of neflamapimod in patients with DLB; the Company&#8217;s need to acquire sufficient funding for any&nbsp;Phase 3&nbsp;trial of neflamapimod in DLB; expectations with respect to neflamapimod, including the timing of any regulatory submissions and potential approvals thereof, if any; the timing of the Company&#8217;s potential submission of an NDA, if any; and the potential market for any DLB treatment that may be approved in the future. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources, the availability of additional funds on acceptable terms, and the Company&#8217;s ability to continue as a going concern; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Contacts</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media:</b><br>
Biongage Communications</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>lisa.guiterman@gmail.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">202-330-3431</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Relations:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors<br>
PJ Kelleher<br>
<u>Investors@cervomed.com</u><br>
617-430-7579</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex_896197.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html><head>
	<title>ex_896197.htm</title>

	<!-- Generated by ThunderDome Portal - 12/5/2025 6:36:48 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Significant reduction in key neurodegeneration biomarker correlated with treatment response,</i> <i>suggesting neflamapimod may act on underlying disease </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB </i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>in the second half of 2026</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BOSTON, December 4, 2025</b> &#8212; Today in a late-breaking oral session at the 18<sup style="vertical-align:top;line-height:120%;">th</sup> Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by CervoMed Inc. (NASDAQ: CRVO) for the treatment of dementia with Lewy bodies (DLB). In the trial, neflamapimod, which targets the neuroinflammation and synaptic dysfunction that are known to drive DLB disease progression, demonstrated a significant and clinically meaningful effect on multiple outcomes in DLB patients, including on the primary outcome measure, change in CDR sum-of-boxes (CDR-SB). These positive clinical outcomes were correlated with observed reductions in glial fibrillary acidic protein (GFAP), a biomarker of neuronal damage, supporting neflamapimod&#8217;s mode of action targeting the underlying mechanism of DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;The magnitude of benefit and consistency of data across clinical measures in RewinD-LB provide great confidence that neflamapimod holds true potential to meaningfully slow clinical progression in DLB, a rapidly progressive disease with profound impact on patients and caregivers,&#8221; said Dr. John-Paul Taylor, MBBS, MRCPsych, PhD, Professor of Translational Dementia Research at Newcastle University and the principal investigator of the RewinD-LB trial for the United Kingdom. &#8220;Importantly, the results build on a growing body of preclinical and clinical evidence supporting neflamapimod&#8217;s potential and give us renewed confidence that we are moving closer to the first approved treatment for patients and their families.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;We&#8217;re pleased to share for the first time with the academic dementia clinical research community the full results of the RewinD-LB trial. These results include new analyses that demonstrate neflamapimod treatment was associated with significant improvements in both clinical and biomarker measures, including CDR-SB, ADCS-CGIC, and plasma GFAP, in within-participant comparisons to placebo in patients with DLB without AD co-pathology,&#8221; said Dr. John Alam, Chief Executive Officer of CervoMed. &#8220;These findings reinforce our conviction in neflamapimod&#8217;s potential and boost our momentum as we prepare to initiate our pivotal Phase 3 trial next year.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results from the Phase 2b RewinD-LB Trial</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The RewinD-LB Phase 2b trial was comprised of an initial, randomized phase comparing neflamapimod to placebo, followed by an open-label, neflamapimod-only extension phase. In the initial phase, the participants did not achieve expected plasma drug concentration levels with the neflamapimod capsules used (DP Batch A), and neflamapimod did not demonstrate a statistically significant improvement on the trial&#8217;s primary endpoint. The lower&#8211;than-expected bioavailability was subsequently determined to be related to the age of the capsules used during this phase of the trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the extension phase, a group of participants received a new batch of capsules that enabled them to achieve target plasma concentration levels (DP Batch B). Several key analyses were performed that evaluated outcomes in participants who received DP Batch B compared with participants who continued to receive DP Batch A during the extension phase. DP Batch A served as a control arm, allowing both across patient and within patient comparisons. Additional pre-specified analyses of the extension phase data were performed based on a &lt;21.0 pg/mL cutoff level of plasma ptau 181, which was externally validated as a high sensitivity cutoff for AD co-pathology earlier in 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Key analyses of the extension phase of the RewinD-LB trial showed:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">A significant improvement on the primary endpoint, CDR-SB (Clinical Dementia Rating Sum of Boxes), at week 16 of the extension phase, with a mean change that was 52% lower with DP Batch B compared to DP Batch A in all participants and 82% lower in patients with a screening plasma ptau181 of &lt;21.0 pg/mL (i.e., patients without AD co-pathology).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The clinical effect in CDR-SB was durable to 32 weeks, with a 65% reduction in clinical worsening in all participants (mean increase=1.73 with DP Batch A vs. 0.53 with DP Batch B) and an 89% reduction in clinical worsening in the &lt;21.0 pg/mL ptau181 subgroup (mean increase=1.44 with DP Batch A vs. 0.16 with DP Batch B).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Compared to placebo, significant improvement was also seen with DP Batch B on change in CDR-SB and the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). Specifically, among patients who transitioned from placebo in the initial phase to DP Batch B in the extension phase, there was improvement with DP Batch B compared to placebo over the respective 16-week treatment periods in change in CDR-SB (difference= 1.12 point improvement vs. placebo, p=0.005) and on the ADCS-CGIC (difference= 0.82 point improvement, p=0.004).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">In in the &lt;21.0 pg/mL ptau181 subgroup, DP Batch B reduced the risk of clinical progression (&#8805;&nbsp;1.5 point increase in CDR-SB) by 75% compared to placebo over 16 weeks of treatment and median time to clinical progression (MTP) increased from 16 weeks for placebo to an estimated 1.5 years with DP Batch B treatment (MTP for DP Batch B not reached and projected based on available data up to 32 weeks).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">During the 32-week extension phase, mean change in plasma glial fibrillary acidic protein<i>&nbsp;</i>(GFAP), a key biomarker of neurodegeneration, was markedly reduced with DP Batch B treatment (median -16.0, IQR: -35, +6.7; p&lt;0.0001) and that reduction was correlated with clinical treatment response. In a within-subject comparison in participants who received placebo during the initial phase and DP Batch B during the extension phase, change in plasma GFAP was significantly lower during treatment (difference = -23.5 pg/mL, p=0.016).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, neflamapimod was well-tolerated with a low rate of treatment discontinuation over 48 weeks of treatment during the trial. During the initial, placebo-controlled phase of the study, 2.5% of neflamapimod recipients discontinued for liver enzyme elevation, and 1.3% of neflamapimod recipients discontinued for liver enzyme elevation during the extension phase. All events of liver enzyme elevation were reversible and none were associated with bilirubin elevation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Trial in Dementia with Lewy Bodies</b><br>
The initial phase of RewinD-LB was a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in 159 participants with DLB, followed by a 32-week neflamapimod-only treatment extension phase. Patients with elevated plasma ptau181 levels at screening were excluded to enrich for patients without AD co-pathology. The primary endpoint in the trial is change in the CDR-SB, and secondary endpoints include the ADCS-CGIC, the Timed Up and Go test, and a cognitive test battery. The RewinD-LB trial was funded primarily by a&nbsp;$21.3 million&nbsp;grant from the&nbsp;National Institutes&nbsp;of Health&#8217;s&nbsp;National Institute on Aging, disbursed over the course of the trial as costs were incurred. The trial included 43 sites across in&nbsp;the United States, the&nbsp;United Kingdom, and&nbsp;the Netherlands.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Dementia with Lewy Bodies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DLB is the second most common progressive dementia after Alzheimer&#8217;s disease, affecting millions worldwide yet there are no approved treatments in the United States (U.S.) or European Union. DLB typically progresses more rapidly than AD, with patients often requiring nursing-home care within two years of diagnosis as they experience a combination of decline in cognitive function, cognitive fluctuations, visual hallucinations, and sleep disorders, as well as motor symptoms similar to Parkinson&#8217;s disease. Individuals without AD co-pathology, often referred to as &#8220;pure&#8221; DLB, represent up to half of the diagnosed patient population and the most significant clinical effects in CervoMed&#8217;s Phase 2a and Phase 2b clinical trials were observed in this subgroup.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral, small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed&#8217;s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB; patients with elevated plasma ptau181 levels at screening were excluded to enrich for patients without AD co-pathology. The Company plans to initiate a global, pivotal Phase 3 trial in substantially the same patient population in the second half of 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Neflamapimod</b><br>
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood&#8211;brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and frontotemporal dementia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In non-clinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week open-label extension, further supported neflamapimod&#8217;s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing a positive effect on a key blood biomarker of neurodegeneration during the extension phase. Across both studies, the greatest benefits were observed in patients with &#8220;pure&#8221; DLB, those without AD co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic effects and the meaningfulness of any correlation between any biomarker and clinical effects; the anticipated timing and achievement of clinical and development milestones, including the Company&#8217;s announcement of additional data or any meeting or correspondence between the Company and the FDA or other regulatory bodies; any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the RewinD-LB trial will be replicated in later trials, including the Company&#8217;s planned&nbsp;Phase 3&nbsp;clinical trial of neflamapimod in patients with DLB; the timing of the initiation of and the design and endpoints of, any potential future trials, including the Company&#8217;s planned&nbsp;Phase 3&nbsp;clinical trial of neflamapimod in patients with DLB; the Company&#8217;s need to acquire sufficient funding for any&nbsp;Phase 3&nbsp;clinical trial of neflamapimod in patients with DLB; expectations with respect to neflamapimod, including the timing of any regulatory submissions and potential approvals thereof, if any; and the potential market for any DLB treatment that may be approved in the future. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources, the availability of additional funds on acceptable terms, and the Company&#8217;s ability to continue as a going concern; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Contacts</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media:</b><br>
Biongage Communications</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>lisa.guiterman@gmail.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">202-330-3431</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Relations:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors<br>
PJ Kelleher<br>
<u>Investors@cervomed.com</u><br>
<u>617-430-7579</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>crvo-20251201.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/5/2025 6:36:39 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:crvo="http://www.crvo.com/20251201" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.crvo.com/20251201">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/cyd-8k-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251201_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251201_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251201_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.crvo.com/20251201/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="crvo_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>crvo-20251201_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/5/2025 6:36:39 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.crvo.com/20251201/role/statement-document-and-entity-information" xlink:href="crvo-20251201.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.crvo.com/20251201/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>crvo-20251201_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/5/2025 6:36:39 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line Two</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>crvo-20251201_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/5/2025 6:36:39 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.crvo.com/20251201/role/statement-document-and-entity-information" xlink:href="crvo-20251201.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.crvo.com/20251201/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logosmlr.jpg
<TEXT>
begin 644 logosmlr.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M<9_"O0-(U6VUK1+35+1@;>ZA69#GH",X/TK.25DT6F[V9SGBSQ;?:9XL\/\
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">CervoMed Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Dec.  01,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">20 Park Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity, Address, Address Line Two</a></td>
<td class="text">Suite 424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-4400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crvo20251205_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crvo.com/20251201/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvo-20251201.xsd</File>
    <File>crvo-20251201_def.xml</File>
    <File>crvo-20251201_lab.xml</File>
    <File>crvo-20251201_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="crvo20251205_8k.htm">crvo20251205_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crvo20251205_8k.htm": {
   "nsprefix": "crvo",
   "nsuri": "http://www.crvo.com/20251201",
   "dts": {
    "schema": {
     "local": [
      "crvo-20251201.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-cr-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "crvo-20251201_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "crvo-20251201_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvo-20251201_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "crvo20251205_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 37,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.crvo.com/20251201/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251205_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251205_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Axis]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentDomain",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Domain]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r8"
     ]
    },
    "cyd_MaterialCybersecurityIncidentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Table]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.crvo.com/20251201/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-25-037025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-037025-xbrl.zip
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M>&ULU5I=C]HX%'U?:?]#-OL<,H&ANZ#2"C&T0IWIH(&JU;ZL3'()5AT;.6:
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MXA1>O.Y4*0NVK64XA0D+LR%2*,EA'%/OM=NXSK30]TSMGTO_O9A\F3=LZ5K
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M&.CFS5:_1[CV;2Q32-619B.-;3J4"((!:K9^Z_^.EO)NQQJ3=5#&$RL-[[%
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MA&>20,,_/QY+Y(_\CVRX\P]02P,$%     @ M("%6\RP1_TN%   /I@  !,
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MW*RW1<X(KU4ECEVA,!D!HL !\8GL=S=J98+_?=@G;WI%8R;W>H7GPNV6?F]
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M[NR;99"T,C?',",\AHEKV#:@KW>=^IR^YAUISSK%X'[2+M=MY17O12B,<KR
M%H^:7;*;W-*AOIB1VG:@O'QM+TLLO7ILG_1NX7_<O3-7F/C,4O@ 1(4%S,,+
MVT)ALE:Q8J864"E9<,>[)[E92[=W3R&]S%C!& <?<1@:21W"=*!$LFNNH!T(
M( T]7'JAGKF##ROC;8 ^E;ZR2^W8?S3WUHH-^B$5LKQD54A&V1>@I$EC?"Q=
M?/GT=7Y:^ X)JE)KJJ_/5YVLLWE6*C? 5-M!SP'"S[[$G!RY^'+V^^G4+(H_
M^2TN%X=?CIU/G>/#K\[AYZOC3I/08$3':GJ32F&VZ1Z8^KWVP&3[6C(,_.-H
M/@80C0^>_]5Y^QO>LGH;!I8QT=+\\:SWD?<IR/1D7M-:Q$Y]KIMVZ_P>TS_$
M<SR:#<E.!2_#6Y:XN7U-X#F![K!^'-BM1Y^/R!%77B!4+-E/L 5U:ED)%TN4
M(ATP,%0Q/ /P9NSO>4BRNW7J]FZ=,BG<.D(VT'3A)MMZ;3_Q4<KFT=U/7X]8
M^@+,9O(N5LF[#^#DJAAZHV J$8_2XK'0\00(4D!VU@<-0U#!J#Z,>8Y 1PXI
MZ7*!#@&T\ZFFI"?%D(A8DHL!#E#O0C<C'AXYWSZ!]4<+GA]S4G:%9=E0/EY6
MA'Z%MJ/U CJ$<&8HT(5@5)OELL#NX.-#-/]F!0VW]D'M6 H>8A-[Q34 [MNW
M/NO;.V7Q+52-X"_3S/@=ONF#4_OTC8W&H$U]],<W4A1]^Y2!B(A$JPI(U<:U
M<'</5!PM4(^H'?&::B>Q<VX=M&VII0<'56@$P1H48G6+!T4 OL/@+Z@,;ME[
MA:)OZ94RP=7A409)6X3)Y:8XITMPYHXXZPM@(A@;_*L0IB1R3)9<X%0AAV!H
MHVSGXB+ZFP!):PK.GP]F6C+ .<489<"[7).]O8IK,#PYWIS4 V# 9\QN7GTS
MX4E>8!NIP([8O62LL5S&]  8RTOY@H?73&G<B"JD(FI )7(_;CB-P4&!ON)
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M44X!+<KTE%.CV^-20>V1P.B ]B6-!M8G7!S"7&5IN4\L9#U07H=*"8\;A66
M^)0E"D]A,/ >C"^2Y3&Q^PV^#.+&K1!GT"X!MI.D2[(P<$ZRTL2#&73&Z;Y5
M!4_LU>X<-\3R@O5%[-\BM+_HE=B_7L0U6:O#I>IP[Y6IP\]9\N0R]0+2B,YD
MWQ9LGE\!%;G"S+BY_>+,>,!;YLL;_ Y77JT.-P+4$[Y;!/H*\-X3FN?)G1 L
MR7^;1*;)4XIBC%.,;C"N,6',^@:)7-];C9<XV=A-V1CO +V? )*[G<%X@2D=
M,>5)'DW=GWS[N8$'D&KQ)N%'/']Y^_Z9*09_]"D^+^EPT75U#[8>4&*_T<EN
M_KV[M^WN;>/W73,5@?LR'= ,DGJZF6A$>QRVX-C;U=3IK1$'5?ID;/KL-*R_
M(AKN/ (-&V^-AFZML;HD; O '[F@?49.</LGD JO?#S"95%S9?D&4L7WDP ]
MB:1/S.?4"7Y//5LQR+:6KY[+MMY&N]Y&^ZC;:!\O#KC#EVE/OIP=7OW>N=O'
M<5]+R)/_=*0](V"63&T>XOZK+>5Y!PW\.!@3C\;*[(+B*EGG3!;$%> <"H3]
M^EF7#6C0PY0==F2R@DD%W' 48_+.= =*>B DS--_J33<^D*,I8>)ISXKL%5[
MS0<)BP$*?KBR.7&6ME)G::Y_\8 O0;P=3.%G<HN?9;SO90Q3N'$?]SCR"WR=
MXD7$Y>%? UD1,+96 XXU^[UF]GM15?AIW+Q=\SWP_I>GE90715E55<D?/ @X
M'9+CP,=/4*U-QUIVGY\1\2Z')=+[$XGE6B37(OGB3&BN9EK+9(J.]H"S'IEL
M*#DWGPN2Y#<ZC/;)%W.8,B#XE6G%@I67V9?.53]S3OS;X>65,\DBS\UR/VKV
M.@4"_DC0/-##H/7_4$L#!!0    ( +2 A5MU;6 F+AD  'MB   -    97A?
M.#DV,3DV+FAT;>U=:7?;1I;]'/^*&O=T(ITF:5'RIL4Z34EVVAW;45O*],<Y
M1:!(5@M ,2A $O/KY[Y7"Q92<MJ=>&(?Y^18%I9:WGK?4O#1HLJSXZ.%DNGQ
M@V^.*EUEZEC=_N_S_:?C_:<CW#UZY"X^^ ;W_VLX%-^K0I6R4JF8KL3EHBY2
M59Z97(ES4U8R$T,QWGWTY-'NSNX3\?1@;WPPWA?G;\5P>'R4JTJ*9"%+JZH7
M#^MJ-GS^T%\M9*Y>/)R9,I?5,%652BIMBH<B,46E"CQ=J4PM%Z90+PKS\/C!
MT2.WYJ.I25?"5JN,7R^JH=6_J(/QSK(ZY%]G,M?9ZN"[2YTK*]ZI&_'>Y++X
M[G ITU07\X,=78C16!>'-.HR#)7+<JZ+ [&SO!4TEJC4;364F9[C8JGG"UQJ
MIA,\GVA/*+[]N3;586]:=Q%3'=&SG76']]96.A!\92"L*O5L;5J,-3U^>;O0
M4UV)_?W1^.C1]/CH$3V%'\OC!P^.4GU]?*3SN9 9*)F9N;%Y5H[^M9P_%+9,
M>I?P%KWPH$6-^RFYB>S7LM2RJ X*XFAVZ,E)MQ\>?UM,[?+0KVWC'/<2[PZZ
MAQF%G[+#L00RI,I#T;"5%@+"G:KRVKR%,)^7RN(A-]UY)FTNQ8G&M.65*L69
MA(Q>+F0E7A>I3B#^]. LD[E<ZMRDXJ0T,LU6;FNO\V5IKOF1NC2ZH.<@UQ!H
M(8O474W5W"D2784(,M>F)4GT\9G*L10MQ8VN%N*-NEF)$Y-J#+AU]N9DVS'X
M;NI]"@[UIO@U,[3XX=G1F?-('X]M)<Q,5#=&+!T[F#S6T0%7Z@P,FI4F%^<+
M:978G6)M-0P WBK:[ "CJH42X^='CS2-?&3KN(UK559@8>;74IGE8:8+-5PH
M4NN#\>[.G[&<:G'T""\=^P'$*9ZAM\0E-I59 :Y-LE_P3J[*[ZPXTU;1BK9.
M+R=GV^+4%#-5JB)1_/Z7R"Q6B53EX$]5LD)T.%"52E8DQB*#=E5&6(RE9R A
M+I4JK1/'6HC^TFG;/ -AQ4Q/2YUELEP)F6CH&D3!5$H71$BQA8F_?S4YWQX(
M*:[42GC]9/[W=&THK36)9E=5]%5NP)JHBZ0DML&7D1.2^2HS.A5;$YILBKFV
MQ>/=1X]W!+]$:X7^?;$</35EJ3)GD4@-H4!J-H,GMFOZ92+7B!M./Y?&ZDI?
MJQ;KH;)+,%F!VA;_6V6MPPVG9^^'%R=P:?5R"=C0'3Q7P B%MCE-*Y-H-VT]
MGRN8"/BY7))X5+0.!B#9"JY<I%X)_P@<^H-*09?GT^.3'R\N?WPW$&<J4?D4
MFK0[$ 3=R,>(;__T?'>\>RBBDWQ=)".Q]6YR<3;YQX$X??\_/[(B)MXV#FTE
MYTI,-10V610&L&(%!)<O9;&"J;A6F5D2GZ* P)B;4N"=(0L>R48IH65@I"G!
M5H >V'EA 1E9B6]$2E:'/0")9_0"[]6-+LZ&;TXP-EF1QB[1?/<;)KG9-)&V
MTQPW.E792M1VDQFAO7H3U-8'DE991/-"0TVF+4LR<'?AB7#S'A/F!G)6R="L
M5ML1N" (NSHS=L?>[,+<8,&2+A6TS1M9IM;MCDCB5\LSSC1&8(*0 P1_9V^V
M":9KF.>,N&9'G[ND7RX )YSPW, O!WBAV))%V1\[V1^TX,-'XX:/!@PD+!<0
MCS.MYA"44\P&)2FT'(D)0@ $1&D''4% LTQ4\DH14]W[>-V4F)IT:CB%4%P1
MS\G\LE"YW27-E&TB/*X6@0P8Z6:ADX4X*T?B[V91#,]EC0U)"&0Y$&]/3B[P
MY_O3<[M*\-+YX@Q_0)XPCV&!OBQE89U'P6HBK'V/U<L2XV(EX&DB+2),\5.A
M22%TM1JX/1&(AO*YQ09JFKI**-KLH,&H_I^]H)+)W=TYA+QV+5';NCB=9-M
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ME"D0I;;!F;C!__)D]#R,S:L>/_6K#F*9ZEDH'+\0P]V]T1/W/!#_"XCE^.E
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M"\=&5F-*CH7Y(*R-E$#@#_?_: VV<Q8V*%PHU):&I,0"7+". B;]=Q0&6O-
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MB)$<OT#51%YE?$2&G!@/1D^'>Y%X_3>8Z,'!823^X^GPV5@L2$$18-H;[3H
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M>%\X.38Q.38N:'1M4$L! A0#%     @ M("%6T*(42F'&0  ]&<   T
M         ( !>4$  &5X7S@Y-C$Y-RYH=&U02P4&      < !P"_ 0  *UL
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>crvo20251205_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crvo-20251201.xsd" xlink:type="simple"/>
    <context id="d20258K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20258K" id="ixv-335">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20258K" id="ixv-336">0001053691</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20258K" id="ixv-346">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20258K" id="ixv-347">2025-12-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20258K" id="ixv-348">CervoMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20258K" id="ixv-349">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20258K" id="ixv-350">001-37942</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20258K" id="ixv-351">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20258K" id="ixv-352">20 Park Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="d20258K" id="ixv-353">Suite 424</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="d20258K" id="ixv-354">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20258K" id="ixv-355">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20258K" id="ixv-356">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20258K" id="ixv-357">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20258K" id="ixv-358">744-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20258K" id="ixv-359">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20258K" id="ixv-360">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20258K" id="ixv-361">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20258K" id="ixv-362">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20258K" id="ixv-363">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20258K" id="ixv-364">CRVO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20258K" id="ixv-365">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20258K" id="ixv-366">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
